AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$AUPH

Robertson Stephen P. sold $356K of AUPH

Robertson Stephen P. (Chief Legal Officer) sold 20,975 shares of Aurinia Pharmaceuticals Inc. (AUPH) at $16.97 ($0.36M total) on 2026-08-21.

Original reporting
SEC EDGAR · Robertson Stephen P.
Published Aug 26, 2026, 1:29 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 1:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AUPH
Bearish
medium confidence
Mentioned
$AUPH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AUPHBearishLow
01

Why it matters

The transaction is a primary disclosure but modest in scale, offering limited trading insight.

02

Market read

Small insider sale with limited price impact.

03

What to watch

No other material news coincides with the filing.

Relevance 4/10Novelty 4/10Timing: post-market 2026-08-21

Background

Form 4 filing by Aurinia's Chief Legal Officer discloses a direct sale of shares.

Company-level read

Ticker impact

$AUPHBearishMedium confidence
Context

Chief Legal Officer sold 20,975 shares for $355,946 on 2026-08-21, reducing his stake.

Expected impact

Potential short-term pressure on AUPH price.

Evidence & confidence

Sale size is modest but insider status adds weight.

Market effects

Sector

Minimal impact on biotech sector.

Regional

None.

Global

Low.

Counterpoint

What could challenge this read

Sale could be routine portfolio rebalancing, not a red flag.

Key entities

  • Company
    Aurinia Pharmaceuticals Inc.

    Biotech firm listed on NASDAQ (AUPH).

  • Executive
    Robertson Stephen P.

    Chief Legal Officer of Aurinia.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AUPH insider trading history →

Related articles

$AUPHMedAI 8/10

Aurinia Skids on Results

Aurinia Pharmaceuticals reported Q3 and YTD 2026 revenue of $83.7M and $244.6M, up 14% and 19% YoY. LUPKYNIS sales rose 12% and 18% YoY for the same periods. License, collaboration, and royalty revenue increased 54% and 39% YoY. Net income before taxes grew 21% and 67% YoY.

baystreet.ca
$AUPHHigh

Aurinia Pharmaceuticals stock falls 3% on Q3 miss, soft guidance

Aurinia Pharmaceuticals (AUPH) reported Q3 earnings of $0.23 per share, missing estimates by $0.01, and revenue of $83.7M, slightly below expectations. Shares fell 3.43% premarket. The company raised 2026 revenue guidance to $325M-$330M, below analyst consensus. LUPKYNIS sales grew 12% YoY to $79.4M. The company also initiated a Phase 4 study for lupus nephritis treatments.

investing.com
$AUPHHigh

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (AUPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress EDMONTON, Alberta – October 30, 2026 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial resul

SEC EDGAR 8-K